OmniAb Revenue Soars 243% in Q1, Significantly Narrows Loss, Raises Full-Year Outlook
Summary
OmniAb, Inc. reported exceptionally strong first-quarter 2026 financial results, with revenue soaring to $14.4 million, a 243% increase from $4.2 million in the prior year period, primarily driven by milestone revenue. The company also significantly narrowed its net loss to $7.7 million ($0.06 per share) from $18.2 million ($0.17 per share) year-over-year. This marks a substantial positive shift compared to the full-year 2025 results which saw a 29% revenue decrease and a large net loss. Furthermore, OmniAb raised its full-year 2026 revenue guidance to a range of $28 million to $33 million, up from $25 million to $30 million, and increased its year-end cash guidance. The positive results were bolstered by strong momentum in partnered programs, including a new license agreement with Florida State University and advancements in clinical development for IMVT-1402 and TEV-'408. This report indicates a significant operational turnaround and improved financial health, which is highly material for the stock. Investors will be watching for topline data from key partnered programs expected in the second half of 2026 and 2027.
At the time of this announcement, OABI was trading at $1.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $212.8M. The 52-week trading range was $1.22 to $2.30. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.